Starton Holdings, Inc.

expected

Not yet set

status

Filed with SEC

proposed ticker

STA

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Underwriters (from filing)

Revere Securities LLC

Overview

— AI-generated from the filing, see note below

Business overview

Starton Holdings, Inc. is a clinical-stage biotechnology company focused on enhancing cancer therapies using proprietary continuous delivery technology systems. The company aims to develop new product formulations for FDA-approved medicines to improve cancer treatment outcomes, specifically targeting hematologic malignancies. Their lead program involves a continuous delivery system for lenalidomide, with indications in multiple myeloma and chronic lymphocytic leukemia, while also exploring other cancer treatments. Additional product candidates are also in various stages of development, leveraging innovative delivery methods to enhance efficacy and patient compliance.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Focus on improving standard-of-care cancer therapies.
Use of a proprietary continuous delivery system to enhance drug delivery.
Targeting off-patent medicines to streamline development costs.
Collaboration with top consulting firms to identify high-potential applications.
Diverse delivery methods (subcutaneous, oral controlled release, transdermal) aimed at improving treatment adherence and outcomes.

Risk factors

No FDA-approved products at current stage.
Dependence on successful completion of clinical trials for regulatory approval.
Potential challenges in achieving superiority in efficacy and safety over existing treatment forms.
Competition from other biotechnology firms targeting similar therapeutic areas.
Regulatory uncertainties regarding the 505(b)(2) pathway may affect approval timelines.

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The proposed ticker is STA. Underwriters on the deal include Revere Securities LLC. Starton Holdings, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Starton Holdings, Inc..

Biotech IPOs United States IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/starton" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Starton Holdings, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/starton?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/starton/opengraph-image

Attribution text

Starton Holdings, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/starton?utm_source=embed&utm_medium=text&utm_campaign=starton

Track this IPO

Get emailed when Starton Holdings, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

What is Starton Holdings, Inc.'s ticker symbol?

Starton Holdings, Inc.'s proposed ticker is STA.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Aug 27, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.